Correction: Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes.

Correction: Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes.

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-11-01
Series:	PLoS Pathogens
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240659/?tool=EBI

Similar Items

Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.
by: Richard Brad Jones, et al.
Published: (2014-08-01)

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
by: Jones, Richard Bradley, et al.
Published: (2014)

Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors
by: Sahu Gautam K, et al.
Published: (2011-08-01)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01)

Design, Synthesis and Cytotoxicity Study of Primary Amides as Histone Deacetylase Inhibitors
by: Duraid Al-Amily, et al.
Published: (2019-12-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
by: Masumeh Sanaei, et al.
Published: (2019-01-01)

OA3-4 LB Elimination of HIV-1 latently infected cells by PKC agonist gnidimacrin alone and in combination with a histone deacetylase inhibitor
by: L. Huang, et al.
Published: (2016-07-01)

Acetylation and Histone Deacetylase Inhibitors in Cancer
by: Madeleine S. Q. Kortenhorst, et al.
Published: (2006-01-01)

Histone deacetylase inhibitors in multiple myeloma
by: Sarah Deleu, et al.
Published: (2009-06-01)

Clinical Toxicities of Histone Deacetylase Inhibitors
by: Richard L. Piekarz, et al.
Published: (2010-08-01)

The application of histone deacetylases inhibitors in glioblastoma
by: Rui Chen, et al.
Published: (2020-07-01)

Histone Deacetylases and their Inhibitors in Cancer Epigenetics
by: Kelly N. Hassell
Published: (2019-11-01)

Antidepressant Actions of Histone Deacetylase Inhibitors
by: Haggarty, Stephen J., et al.
Published: (2010)

Medicinal chemistry of histone deacetylase inhibitors
by: Ružić Dušan, et al.
Published: (2021-01-01)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells
by: Elisabetta Mattioli, et al.
Published: (2019-01-01)

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
by: Androniki Kretsovali, et al.
Published: (2012-01-01)

The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
by: Jan M Klein, et al.
Published: (2013-01-01)

Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors
by: Ryosuke Ushio, et al.
Published: (2022-03-01)

Role of histone deacetylases and their inhibitors in neurological diseases
by: Li-Ying Zhang, et al.
Published: (2024-10-01)

Histone Deacetylase Inhibitors from Marine Invertebrates
by: Claudio Luparello, et al.
Published: (2020-11-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
by: Ehab Ghazy, et al.
Published: (2022-01-01)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
by: Duong Tien Anh, et al.
Published: (2023-02-01)

The effect of histone deacetylase inhibitors on AHSP expression.
by: Mohammad Ali Okhovat, et al.
Published: (2018-01-01)

Zinc binding groups for histone deacetylase inhibitors
by: Lei Zhang, et al.
Published: (2018-01-01)

Dual Inhibitors Targeting DNA and Histone Deacetylases
by: Chen Chen, et al.
Published: (2020-06-01)

Attenuation of choroidal neovascularization by histone deacetylase inhibitor.
by: Nymph Chan, et al.
Published: (2015-01-01)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
by: H. Miles Prince, et al.
Published: (2010-08-01)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
by: Madhumanti Barman, et al.
Published: (2021-11-01)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
by: Guo Li, et al.
Published: (2020-09-01)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
by: Guang Lu, et al.
Published: (2023-08-01)

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
by: Sheila López-Cobo, et al.
Published: (2018-02-01)

Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review
by: Yingjun Zhang, et al.
Published: (2024-02-01)

PB1856: DEMETHYLATING AGENTS AND HISTONE DEACETYLASE INHIBITORS AS NEW THERAPEUTIC STRATEGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA
by: J. Jorge #, et al.
Published: (2022-06-01)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells
by: Basile Stamatopoulos, et al.
Published: (2010-07-01)

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives
by: Jingjing Pu, et al.
Published: (2024-04-01)

Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia
by: Mohammad Amin Akbarzadeh, et al.
Published: (2024-12-01)

Role of histone deacetylase inhibitors in non-neoplastic diseases
by: Chunxiao Zhou, et al.
Published: (2024-07-01)

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke
by: Svetlana Demyanenko, et al.
Published: (2021-10-01)

HDACiDB: a database for histone deacetylase inhibitors
by: Murugan K, et al.
Published: (2015-04-01)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
by: Fengyi Guo, et al.
Published: (2022-11-01)